Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
AstraZeneca
(NASDAQ:AZN)
Intraday
$75.23
0.20
[0.27%]
After-Hours
$75.23
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$75.23
0.20
[0.27%]
At close: Apr 26
$75.23
0
[0.00%]
After Hours: 4:25PM EDT
Get Report
Watch
Q1 2024 Earnings were released on Thu Apr 25th, before the market open
The most recent conference call was at 6:45 AM, 2 days ago
Click to view past webcast
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for AstraZeneca Stock (NASDAQ:AZN)
AstraZeneca Stock (NASDAQ: AZN)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, April 26, 2024
BMO Capital Maintains Outperform on AstraZeneca, Raises Price Target to $82
Benzinga Newsdesk
-
1 day ago
Top 4 Health Care Stocks That May Plunge This Month
Avi Kapoor
-
1 day ago
Thursday, April 25, 2024
AstraZeneca, Through A Subsidiary, Will Acquire All Of Fusion's Outstanding Shares For A Price Of $21.00 Per Share In Cash At Closing Plus A Non-Transferable CVR Representing The Contingent Right To Receive $3.00/Share In Cash Payable Upon The Achievement Of A Specified Regulatory Milestone, Pursuant And Subject To The Terms And Conditions Of A Contingent Value Rights Agreement
Benzinga Newsdesk
-
2 days ago
Is "Bad News" Still "Good News" for the Market?
Zacks
-
2 days ago
Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Avi Kapoor
-
2 days ago
Stocks Drop, Tech Tumbles With Meta's Weak Outlook, Q1 Stagflation Fears; Gold Miners Advance: What's Driving Markets Thursday?
Piero Cingari
-
2 days ago
Sanofi Reports Strong Earnings, Joins Kirby, Sonic Automotive, Union Pacific And Other Big Stocks Moving Higher On Thursday
Avi Kapoor
-
2 days ago
AstraZeneca Posts Bumper Earnings On Strong Sales From Cancer Drugs, Sticks To Annual Guidance
Vandana Singh
-
2 days ago
US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst
Shanthi Rexaline
-
2 days ago
AstraZeneca shares are trading higher following a Q1 revenue beat.
Benzinga Newsdesk
-
2 days ago
AstraZeneca Reiterates Its 2024 Guidance: Expects Total Revenue And Core EPS To Increase By A Low Double-Digit To Low Teens Percentage At CER
Benzinga Newsdesk
-
2 days ago
AstraZeneca Q1 2024 Adj EPADS $1.03 Misses $1.22 Estimate, Sales $12.679B Beat $11.833B Estimate
Benzinga Newsdesk
-
2 days ago
Wednesday, April 24, 2024
AstraZeneca Awarded $913M Contract By The Department Of Veteran Affairs For BTK Inhibitors
Benzinga Newsdesk
-
3 days ago
Angle Inks New Commercial Agreement With AstraZeneca to Enhance DNA Damage Response Detection
Benzinga Newsdesk
-
3 days ago
Tuesday, April 23, 2024
The European Commission Has Approved AstraZeneca's Voydeya (Danicopan) As An Add-on To Ravulizumab Or Eculizumab For Paroxysmal Nocturnal Hemoglobinuria Patients Who Have Residual Hemolytic Anemia
Benzinga Newsdesk
-
4 days ago
Monday, April 22, 2024
Insights Into Astrazeneca Q1: Wall Street Projections for Key Metrics
Zacks
-
5 days ago
Sunday, April 21, 2024
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
Shanthi Rexaline
-
6 days ago
Friday, April 19, 2024
Looking At AstraZeneca's Recent Unusual Options Activity
Benzinga Insights
-
Apr 19, 2024, 4:45PM
Brexit Impact On Drugs - Rising Shortages in UK Highlight Brexit Challenges
Vandana Singh
-
Apr 19, 2024, 11:39AM
Wednesday, April 17, 2024
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
Vandana Singh
-
Apr 17, 2024, 2:39PM
Tuesday, April 16, 2024
Deutsche Bank Upgrades AstraZeneca to Hold
Benzinga Newsdesk
-
Apr 16, 2024, 2:17PM
AstraZeneca's Imfinzi/Chemo Combo Doubles Overall Survival In Biliary Tract Cancer Patients At 3 Years, Data Shows
Vandana Singh
-
Apr 16, 2024, 8:53AM
AstraZeneca's Imfinzi Plus Chemotherapy Doubled Overall Survival Rate At Three Years For Patients With Advanced Biliary Tract Cancer In TOPAZ-1 Phase 3 Trial
Benzinga Newsdesk
-
Apr 16, 2024, 5:22AM
Friday, April 12, 2024
Novo Nordisk/Eli Lilly's Weight Loss Drugs Does Not Cause Suicidal Behaviors - After FDA, European Medicines Agency Says
Vandana Singh
-
Apr 12, 2024, 10:40AM
Thursday, April 11, 2024
AstraZeneca Hikes Annual Dividend By 7% Just Before Vote On Its CEO's Pay Package Boost
Vandana Singh
-
Apr 11, 2024, 9:04AM
AstraZeneca shares are trading higher following FDA approval of FASENRA. Additionally, the company raised its 2024 dividend by 7%.
Benzinga Newsdesk
-
Apr 11, 2024, 8:50AM
FDA Approves AstraZeneca's Fasenra (Benralizumab) For Add-on Maintenance Treatment For Patients With Severe Asthma Aged 6 To 11 With An Eosinophilic Phenotype
Benzinga Newsdesk
-
Apr 11, 2024, 7:02AM
Earlier Astrazeneca Announced Increase In 2024 Dividend By 7% To $3.10/Share
Charles Gross
-
Apr 11, 2024, 5:17AM
Monday, April 08, 2024
AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor
Vandana Singh
-
Apr 8, 2024, 10:34AM
Sunday, April 07, 2024
US Manufacturing Hits 18-Month High, China's Growth Could Trigger Deflation And More: Economics Weekly Roundup
Benzinga Neuro
-
Apr 7, 2024, 6:03AM
Friday, April 05, 2024
FDA Grants Accelerated Approval To ENHERTU For Unresectable Or Metastatic HER2-Positive Solid Tumors
Benzinga Newsdesk
-
Apr 5, 2024, 3:30PM
New Hope for Aggressive Lung Cancer: AstraZeneca's Imfinzi Shows Promising Results in Phase 3 Trial
Vandana Singh
-
Apr 5, 2024, 10:19AM
US Labor Market Heats Up In March: Payrolls Grow By 303,000, Highest In 10 Months, Dampen June Rate Cut Hopes (UPDATED)
Piero Cingari
-
Apr 5, 2024, 9:18AM
AstraZeneca Says Imfinzi Significantly Improved Overall Survival And Progression-free Survival For Patients With Limited-Stage Small Cell Lung Cancer In ADRIATIC Phase 3 Trial
Benzinga Newsdesk
-
Apr 5, 2024, 6:51AM
Wednesday, April 03, 2024
A Closer Look at AstraZeneca's Options Market Dynamics
Benzinga Insights
-
Apr 3, 2024, 11:01AM
Tuesday, April 02, 2024
AstraZeneca CEO Highlights Decade-Long Sales Goal Of $45B Along With Investor Doubts As It Lags In Weight Loss Race
Vandana Singh
-
Apr 2, 2024, 2:54PM
Daiichi Sankyo And AstraZeneca's Datopotamab Deruxtecan Moves Forward In The Fight Against Metastatic Breast Cancer With U.S. BLA Acceptance
Benzinga Newsdesk
-
Apr 2, 2024, 2:18AM
Monday, April 01, 2024
FDA Approves AstraZeneca's Voydeya (Danicopan) As Add-On Therapy To Ravulizumab Or Eculizumab For Extravascular Hemolysis In Adults With Paroxysmal Nocturnal Hemoglobinuria
Benzinga Newsdesk
-
Apr 1, 2024, 4:15AM
Wednesday, March 27, 2024
What's Going On European Pharma Giant AstraZeneca Stock On Wednesday?
Vandana Singh
-
Mar 27, 2024, 1:42PM
AstraZeneca Announced Earlier, Truqap Plus Faslodex Approved In Japan For Patients With Advanced HR-positive Breast Cancer
Charles Gross
-
Mar 27, 2024, 4:56AM
Monday, March 25, 2024
FDA Approves AstraZeneca's Ultomiris (Ravulizumab-cwvz) For Adult Patients With Anti-Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder
Benzinga Newsdesk
-
Mar 25, 2024, 4:30AM
Thursday, March 21, 2024
AstraZeneca Says Saphnelo Shows Higher Rates Of Remission In Patients With Systemic Lupus Erythematosus Vs Standard Therapy Alone Over 4-Year Period
Benzinga Newsdesk
-
Mar 21, 2024, 3:49PM
EXCLUSIVE: 2024 Witnesses Increase In Biotech Initial Public Offerings
Abbey Higginbotham
-
Mar 21, 2024, 3:04PM
After Failed Prostate Cancer Study Merck's Keytruda Combination Therapy Flunks In Late-Stage Lung Cancer Study
Vandana Singh
-
Mar 21, 2024, 2:46PM
Tagrisso With The Addition Of Chemotherapy Showed Favourable Trend In Overall Survival In EGFR-Mutated Advanced Lung Cancer With Further Follow Up In FLAURA2 Phase III Trial
Benzinga Newsdesk
-
Mar 21, 2024, 10:16AM
Senator Bernie Sanders Applauds GSK's Move To Cap Inhaler Costs At $35 Per Month
Vandana Singh
-
Mar 21, 2024, 7:17AM
Tuesday, March 19, 2024
AstraZeneca Files For Debt Shelf; Size Not Disclosed
Benzinga Newsdesk
-
Mar 19, 2024, 5:00PM
Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform
Vandana Singh
-
Mar 19, 2024, 2:16PM
AstraZeneca's $2.4B Fusion Pharmaceuticals' Acquisition Signals Shift In Efforts From Traditional Regimens For More Targeted Cancer Treatments
Vandana Singh
-
Mar 19, 2024, 7:26AM
Fusion Pharmaceuticals to be Acquired by AstraZeneca for $2B Plus Milestones in Oncology Breakthrough
Benzinga Newsdesk
-
Mar 19, 2024, 3:06AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch